- Home
- AKTX vs FGNX Comparison
AKTX vs FGNX Comparison
Compare AKTX & FGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- FGNX
- Stock Information
- Founded
- AKTX N/A
- FGNX 1932
- Country
- AKTX United States
- FGNX United States
- Employees
- AKTX N/A
- FGNX N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- FGNX Property-Casualty Insurers
- Sector
- AKTX Health Care
- FGNX Finance
- Exchange
- AKTX Nasdaq
- FGNX Nasdaq
- Market Cap
- AKTX 25.1M
- FGNX 25.2M
- IPO Year
- AKTX N/A
- FGNX N/A
- Fundamental
- Price
- AKTX $0.72
- FGNX $3.74
- Analyst Decision
- AKTX Strong Buy
- FGNX Strong Buy
- Analyst Count
- AKTX 2
- FGNX 1
- Target Price
- AKTX $3.30
- FGNX $8.00
- AVG Volume (30 Days)
- AKTX 117.8K
- FGNX 1.0M
- Earning Date
- AKTX 11-18-2025
- FGNX 11-19-2025
- Dividend Yield
- AKTX N/A
- FGNX N/A
- EPS Growth
- AKTX N/A
- FGNX N/A
- EPS
- AKTX N/A
- FGNX 2.41
- Revenue
- AKTX N/A
- FGNX $24,184,000.00
- Revenue This Year
- AKTX N/A
- FGNX N/A
- Revenue Next Year
- AKTX N/A
- FGNX N/A
- P/E Ratio
- AKTX N/A
- FGNX $1.54
- Revenue Growth
- AKTX N/A
- FGNX 24.03
- 52 Week Low
- AKTX $0.57
- FGNX $3.35
- 52 Week High
- AKTX $3.15
- FGNX $41.25
- Technical
- Relative Strength Index (RSI)
- AKTX 36.32
- FGNX N/A
- Support Level
- AKTX $0.76
- FGNX N/A
- Resistance Level
- AKTX $0.79
- FGNX N/A
- Average True Range (ATR)
- AKTX 0.07
- FGNX 0.00
- MACD
- AKTX -0.03
- FGNX 0.00
- Stochastic Oscillator
- AKTX 0.00
- FGNX 0.00
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.